TLN-372 + pembrolizumab

TLN-372 + pembrolizumab is an investigational combination therapy being developed by Treeline Biosciences for the treatment of advanced KRAS mutant solid tumors. TLN-372 is a small molecule pan-KRAS inhibitor designed to provide deep and continuous inhibition across multiple KRAS mutations, including those beyond the G12C variant. Pembrolizumab is a well-established monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance the body's anti-tumor immune response. The combination is currently being evaluated in a Phase 1 clinical trial to assess its safety, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors harboring KRAS mutations, aiming to leverage the synergy between direct oncogene inhibition and immune system activation.

Other names

TLN372 + pembrolizumabTLN-372 plus pembrolizumabTLN372 plus pembrolizumabTLN 372 plus pembrolizumab